Please ensure Javascript is enabled for purposes of website accessibility
network member

Florida

About Network Member

Currently Enrolling

HCRN-GI23-617

Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors.
Cancer areas:Small Bowel
Atlantic Health System
Moffitt Cancer Center
Parkview Research Center
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine
University of Illinois Cancer Center
UT Southwestern Harold C. Simmons Comprehensive Cancer Center
Virginia Commonwealth University
Currently Enrolling

HCRN-GU21-551

ENHANCE (Elevated NKG2A and HLA-E Amplify NK/CD8 Checkpoint Engagers): A Phase 2 Trial of Durvalumab (MEDI4736) plus Monalizumab in Non-Muscle-Invasive Bladder Cancer
Cancer areas:Bladder
Icahn School of Medicine at Mount Sinai
Moffitt Cancer Center
Rutgers Cancer Institute
UC San Francisco
Weill Cornell Medicine
Currently Enrolling

HCRN-AML20-472

TAGALONG Trial: Phase II Study of TAGraxofusp and Azacitidine With or Without Venetoclax in Newly Diagnosed Secondary AML after Previous Exposure to HypOmethylatiNG Agents
Cancer areas:Leukemia
AdventHealth Orlando
Penn Medicine Abramson Cancer Center
Rhode Island Hospital
Roswell Park Cancer Institute
Sylvester Comprehensive Cancer Center at the University of Miami
University of North Carolina Lineberger Comprehensive Cancer Center
Wake Forest Baptist Medical Center Comprehensive Cancer Center
Enrollment Closed

HCRN-BRE18-360

Phase I/II Study of Stereotactic Radiosurgery With Concurrent Administration of DNA Damage Response (DDR) Inhibitor (OLAparib) Followed by Adjuvant Combination of DuRvalumab (MEDI4736) and Physician’s Choice Systemic Therapy in Subjects With BreAst Cancer Brain Metastases
Cancer areas:Breast
Cleveland Clinic Cancer Center
Duke Cancer Institute
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Memorial Breast Cancer Center at Memorial Regional Hospital
Memorial Sloan Kettering Cancer Center
University of North Carolina Lineberger Comprehensive Cancer Center
Currently Enrolling

BTCRC-LUN18-153

A Randomized Phase II Trial of Adjuvant Pembrolizumab Versus Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm
Cancer areas:Lung
Fred & Pamela Buffett Cancer Center
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
Masonic Cancer Center, University of Minnesota
Moffitt Cancer Center
Penn State Cancer Institute
Providence Cancer Institute
Rutgers Cancer Institute
University of Illinois Cancer Center
University of Iowa Holden Comprehensive Cancer Center
University of Virginia Cancer Center
Enrollment Closed

HCRN-LUN18-335

An Open-Label Randomized Phase II Study of Combining Osimertinib with and without Ramucirumab in TKI-naïve EGFR-mutant Locally Advanced or Metastatic NSCLC
Cancer areas:Lung
MD Anderson Cancer Center
Moffitt Cancer Center